Regenerating blood vessels gets $2.7 million grant

April 26, 2016

Biomedical engineers in the Cockrell School of Engineering at The University of Texas at Austin have received a three-year, $2.7 million grant from the U.S. Department of Defense (DOD) to advance a promising treatment that could help millions of older Americans and people with diabetes affected by peripheral ischemia, a condition that restricts blood flow to muscles in the lower limbs.

There are more than 3 million reported cases of peripheral vascular disease (PVD) annually in the United States. People over 65 years old, people with diabetes and smokers are most at risk for the condition, which causes peripheral ischemia.

Peripheral ischemia occurs when blockages in arteries or vessels, reduce the supply of blood and oxygen to tissues in the legs and feet. Left untreated, peripheral ischemia can lead to gangrene and amputation. To combat this condition, the UT Austin researchers have developed an injectable, regenerative gel that delivers a combination of sugar-containing proteins called proteoglycans and a growth factor to stimulate the growth of blood vessels and restore blood flow in the lower limbs.

Aaron Baker, associate professor in the Department of Biomedical Engineering, and his research team will receive the funding from the DOD's Congressionally Directed Medical Research Programs, created to foster novel approaches to biomedical research. The grant will bolster the development of the team's ischemia treatment and support it through pre-clinical testing to bring the treatment closer to human clinical trials and a commercialized therapy.

Baker is collaborating on the pre-clinical trials with UT Austin biomedical engineering professor Andrew Dunn and Richard Smalling, cardiologist at the McGovern Medical School at The University of Texas Health Science Center at Houston.

"Ischemia is a huge problem for people with diabetes and leads to many issues, including non-healing wounds and the eventual need to amputate limbs, in severe cases," Baker said. "The purpose of our research is to develop a successful therapy, a gel that can be injected into the leg so blood vessels can grow back."

Physical therapy, medicine and bypass surgery, which can be performed in the legs to unclog arteries or vessels, can provide temporary relief for patients with severe PVD and the accompanying peripheral ischemia, but there is currently no long-term treatment option.

"Our treatment is different from existing options in that you are going to grow new, small vessels that will take the place of the old ones that aren't working well," Baker said.

While there has been great interest from researchers nationwide to deliver growth factors to induce angiogenesis -- the growth of blood vessels -- other therapies in clinical trials have achieved only limited success in patients.

Baker and his team suspected that these treatments were lacking a key protein that would trigger the growth factors to build blood vessels. During their research, they discovered that diabetic mice were missing proteoglycans, a protein with several sugar chains, which provides signals to the growth factors to grow the blood vessels.

"The idea was to give a growth factor that induces angiogenesis, and also to find the missing piece, proteoglycan, which makes it work," Baker said.

In experiments, their newly designed therapy successfully grew blood vessels in mice with ischemia and diabetes, and resulted in 85 percent recovery of blood vessels in the mice, compared with 60 percent recovery reported by other growth factor-based treatments. Baker and his team published their work in Advanced Healthcare Materials Feb.18.

"We believe our treatment could also be used as a platform to treat the complications of diabetes, including non-healing wounds and myocardial ischemia, which causes obstructions in the heart," Baker said.

In the months and years ahead, the research group plans to optimize the treatment and determine the proper dosing and delivery mechanism before moving the patent-pending therapy into human clinical trials.
-end-


University of Texas at Austin

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.